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Mycotoxicoses are acute and chronic poisonings caused by mould toxins called mycotoxins. Although 
acute mycotoxicoses, caused by high mycotoxin levels in food are rare nowadays, they need to be described 
in order to inform physicians and other health care workers about their symptoms. Children are more 
sensitive to mycotoxins because of their lower body mass, higher metabolic rate, and underdeveloped 
organ functions and detoxication mechanisms. Some mycotoxicoses appear only in children, and some 
are more pronounced in children than in adults. Acute mycotoxicoses in children are reported poorly, 
mostly because they occur in the tropical regions with poor healthcare coverage. In developed countries 
healthcare authorities are more concerned about child exposure to low levels of mycotoxins with 
immunotoxic, genotoxic or carcinogenic properties.
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Mycotoxins are the metabolites of moulds (fungi 
imperfecti) that contaminate food and feed around the 
world. Humans are continuously exposed to 
mycotoxins, as not even good agricultural and 
production practices can entirely prevent their 
production. Mould growth and the production of 
mycotoxins depend on the genetic properties of 
individual mould species and on environmental 
conditions such as temperature, humidity, and insect 
infestation. Grains are usually contaminated with 
several mycotoxins, which may either be the 
consequence of contamination with several strains of 
moulds, each producing its own mycotoxin, or of the 
production of several mycotoxins by one mould 
species. Out of about 400 known mycotoxins, only a 
few have been investigated in detail in laboratory 
animals and even fewer have known toxic and other 
health-threatening effects in humans.
The main route of exposure in humans is ingestion 
of contaminated food, but for some mycotoxins 
inhalation or dermal exposure are also possible. It is 
very difficult to assess the health risks associated with 
mycotoxins in children, as reliable exposure data are 
seldom available, mycotoxins often occur with other 
mycotoxins or other toxins, other dietary elements and 
contaminants affect their toxicity, and many diseases 
induced by mycotoxins have long latency (1).
For most mycotoxins there are no epidemiological 
data on their carcinogenicity in humans, but for some 
(such as aflatoxin B1) there is convincing evidence of 
an association with human hepatocellular carcinoma. 
Other mycotoxins (such as ochratoxin A, patulin, and 
fumonisin B1) are suspected to be human carcinogens 
due to positive results in experimental animals (2). 
Young animals and children are more sensitive to the 
adverse effects of mycotoxins than adults because of 
lower body mass, higher metabolic rate, and 
underdeveloped organ functions and detoxication 
mechanisms.
Most mycotoxins may cause acute and chronic 
mycotoxicoses. Acute mycotoxicoses are serious 
diseases caused by exposure to very high mycotoxin 
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levels. They are most common in tropical regions 
where exposure of children to certain mycotoxins, 
particularly aflatoxins, is continuously high. 
Conversely, chronic mycotoxicoses are associated 
with low-level exposure. Mycotoxicoses are important 
differential diagnoses and should be taken into 
consideration when a clinical disorder affects a group 
of persons in whom it cannot be related to an infectious 
agent.
Even though clinical symptoms and the outcome 
are more severe in children than adults, mycotoxicosis 
reports seldom distinguish the two groups.
This article is an attempt to review what little is 
known about mycotoxicosis in children and the 
available data on mycotoxins and biomarkers of 
exposure to mycotoxins in various biological materials 
(blood of pregnant women, umbilical cord blood, 
blood and urine of children).
Aflatoxins
Aflatoxins B1 (AFB1), B2 (AFB2), G1 (AFG1), 
and G2 (AFG2) are mycotoxins produced by 
Aspergillus spp. Their names come from the colour 
of their fluorescence (B - blue, G - green). The most 
common and also the most toxic is AFB1. In the 
organism, AFB1 and AFG1 are metabolised to various 
compounds, including aflatoxin M1 (AFM1) and M2 
(AFM2), which appear in human and cow milk, urine, 
and faeces.
Aflatoxins contaminate nuts, maize, sorghum, 
millet, beans, cassava, and rice, whereas their 
metabolites AFM1 and AFM2 contaminate milk and 
dairy products.
Animal studies show that, apart from being acutely 
toxic, aflatoxins are immunosuppressive, mutagenic, 
teratogenic, and carcinogenic (2). The target organ of 
their toxicity and carcinogenicity is the liver. The 
International Agency for Research on Cancer (IARC) 
has classified natural mixtures of AFs as carcinogenic 
in humans (Group 1) and AFM1 as potentially 
carcinogenic in humans (Group 2) (2).
Aflatoxins are well absorbed by the gastrointestinal 
(GI) tract and transported to the liver, where they are 
metabolised by a number of competitive pathways. 
They are bioactivated mainly by cytochrome P450 
(CYP) 3A enzymes (CYP3A4, CYP3A5, and 
CYP3A7) in the first oxidative phase. AF activation 
is also possible in the small intestine due to the 
presence of CYP3A4 and CYP3A5. About 1-3 % of 
the absorbed AFs is activated to highly mutagenic 
exo-epoxide (AFB1-8,9-epoxide), whose half-life (t1/2) 
is only one second in aqueous buffer but long enough 
to react with DNA to yield 98 % of the N7-guanyl 
adduct. Wojnowski et al. (4) have associated high 
levels of the mutagenic AFB1 exo-8,9-epoxide in 
humans exposed to dietary AFB1 with the CYP3A5 
polymorphism, particularly in individuals with low 
CYP3A4. AFB1 8,9-epoxides hydrolyse to non-
genotoxic dihydrodiol, which is further metabolised 
to its dialdehyde (5). The amount of AFB1-DNA 
adducts is greater in the liver than in other organs and 
generally correlates with AFB1 levels and species 
susceptibility to hepatocarcinogenesis (6). DNA- and 
albumin-AFB1 adducts (AFB1-DNA, AFB1-alb) are 
reliable biomarkers of long-term exposure to AFB1. 
The major detoxication route for AFB1 metabolites is 
via conjugation with glutathione (GSH) to form the 
AFB1-GSH conjugate excreted in urine and bile, and 
this reaction determines species resistance to aflatoxin 
toxicity (7).
In some regions of Africa and Asia the risk of 
hepatocellular carcinoma (HCC) is very high, 
particularly in hepatitis B surface antigen-positive 
(HBsAg+) persons. Without AF exposure, the relative 
risk of HCC development in HBsAg+ persons is 7.3, 
but with AFs exposure it soars to about 60 (8). In 
adults, AFs cause deletional mutations in the P53 
tumour-suppressing gene and therefore activate 
oncogenes. However, in two to five-year-old children 
in Guinea with high AF-albumin adduct levels Turner 
et al. (9) found no mutations in P53 tumour-
suppressing gene, which suggests that children could 
be protected from high AF carcinogenicity if 
vaccinated against HBV infection, as it significantly 
increases the risk of HCC. In order to decrease the 
risk of HCC, South Africa has recently introduced 
vaccination against HBV infection in infants 
(receiving three shots by their 14th week). In a five-year 
follow up Tsebe et al. (10) reported that this 
vaccination decreased significantly the HBsAg+ carrier 
rate in children younger than five years.
Exposure to AFs may be assessed by measuring 
parent compound or metabolites in blood and urine, 
or AFB1-alb and AFB1-DNA adducts in blood. The 
first method is only reliable for recent exposure to AFs 
because of their fast metabolism and therefore a 
tendency to underestimate longer exposure. This is 
probably why there were no AFB1-positive urine 
findings in children from Cameroon, even though 11 % 
of the samples showed the presence of its metabolite 
AFM1 (11). The second method that measures AF-alb 
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and AF-DNA adducts is therefore more reliable for 
longer exposures (2-3 months).
Aflatoxicosis is a clinical condition following 
exposure to aflatoxins. Acute aflatoxicosis is a severe 
poisoning that results in serious liver damage, often 
with fatal outcome. Chronic aflatoxicosis is the 
consequence of exposure to lower levels of AFs over 
a longer period and may have chronic nutritional and 
immunological consequences. In terms of cancer risk, 
the effects are cumulative.
The first report of acute AF hepatotoxicity in 
children dates back to 1971 (12), when 20 malnourished 
children from 1.5 to 5 years of age were hospitalised 
for symptoms of acute liver damage, 13 of whom were 
subicteric. They had been eating a peanut protein meal 
contaminated with aflatoxin (30 μg kg-1) from five 
days to one month. At the end of the one-year follow 
up, 12 had gross hepatomegaly and three had palpable 
liver with sharp edges. Three children died from 
hepatic coma after 1.5 years.
Another outbreak of acute aflatoxicosis in India in 
1974 practically spared the children under the age of 
five years, who made about 8 % of the affected patients 
(13,14). In the most severe aflatoxicosis outbreak in 
Kenya in 1981, the number of affected children was 
never established (15), but in the outbreak of 2004, it 
was half of those whose age data was known (308 of 
317 people). Sixty eight children were under the age 
of five and 90 from five to fifteen (16).
Exposure to AFs in utero in Africa is alarming 
(Table 1). The findings of AFs in umbilical cord blood 
from 1988 were the first to evidence transplacental 
transport of AFs in humans (17). Egyptian researchers 
established a significant negative correlation between 
birth weight and AF levels in umbilical cord blood 
(18, 20). In Gambia, a negative correlation was also 
found between AF-albumin adduct levels in mother’s 
blood and weight and height gain in the first year of 
child’s life (19).
It is estimated that up to 0.43 % of AFs from 
consumed food is excreted as AFM1 in breast milk 
(21) and that mothers’ exposure to AFs depends on 
their socioeconomic status (22, 23). In African 
countries, Turkey, Iran, and United Arab Emirates the 
frequency of AF-positive breast milk samples is rather 
high (Table 2). In Egypt and Gambia the concentrations 
of AFM1 in breast milk showed great seasonal 
variations (16-96 %), peaking in the dry season 
(summer) (26, 41). Breastfed children in Africa are 
exposed to lower AF concentrations than weaning 
children because the staple food in the weaning period 
is maize and cassava, which are often contaminated 
with AFs (21, 42, 43). In Europe the frequency of 
AFM1-positive breast milk samples does not exceed 
5 %, and the AFM1 levels are much lower than in 
Africa, but they still exceed the maximum tolerance 
limit for infant formula, follow-up formula, infant 
milk, and follow-up milk of 0.025 µg kg-1 in some 
European countries (44, 45).
Similar to breast milk, the frequency of AF-
positive blood and urine samples of African children 
is high, and AF concentrations peak in the summer 
(Tables 3 and 4). In children from Gambia AF-albumin 
adduct levels in the summer are twice as high as in 
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Positive by toxin 
(N, positive samples/analysed, mean and range in ng L-1, where available) Ref.
B1 B2 M1 M2 Method
Ghana* 63/188 (34 %) 17/188 (9 %) (185-43,822)
17/188 (9 %) 
(11-925)
21/188 (11 %) 
(34-7,320)
21/188 (11 %) 
(30-572) HPLC-FD 17
Nigeria 9/78 (11 %) ND 1/78 (1 %) 10
3/78 (4 %)  
(25-8,942)










107/201 (53 %) 
X=1,108  
(110-4,060)




Gambia** 49/99 (48 %)





ND–not detected; HPLC-FD–High pressure liquid chromatography with fluorescent detection; ELISA–enzyme-linked immunosorbent 
assay
*In addition, AFG1 was detected in three samples (611, 1354, and 354 ng L-1) and AFG2 in one (37 ng L-1)
**AF-alb adducts (pg mg-1 of protein)
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Table 2 Frequency of AFM1- and AFM2-positive breast milk samples and their concentrations across the continents
Country No. positive/analysed
No. positive/analysed  
(range ng L-1) Method Ref.
AFM1 AFM2
Africa
Cameroon 3/62 (4.8 %) 3/62 (4.8 %)  (5.0-62.5) HPLC-FD 24
Egypt
Apr-Jun 23/37 (62 %) 23/37 (62 %) X=0.35 (0.3-2.1)
HPLC-FD 25
Sep-Dec 16/45 (35 %) 16/45 (35 %) X=0.34 (0.3-1.9)
Jan-May 27/38 (71 %) 27/38 (71 %) X=0.3 (0.2-1.6)
Total 66/120 (55 %)
248/443 (56 %) 248/443 (56 %) (4.2-889) HPLC-FD 26
87/125 (70 %) 87/125 (70 %) X=74.4 (73-328) ELISA 27
Ghana 90/264 (34 %) 59/264 (22 %)  (20-1,816)
18/264 (7 %) 
(16-2,075) HPLC-FD 17
Nigeria 41/50 (82 %) 41/50 (82 %) (4.62-92.14) HPLC-FD 22
Sudan*
37/99 (37 %) 26/99 (26 %) X=19.0
24/99 (24 %) 
X=12.2 HPLC-FD 28
51/94 (54 %) 51/94 (54 %) X=0.41 HPLC-FD 29
Zimbabwe 6/54 (11 %) 6/54 (11 %)  (0.2-50) ELISA 30
Middle East
Jordan 100/100 (100 %) 100/100** (100 %) X=68 ELISA 31
United Arab 
Emirates 144/201 (71 %)
107/201 (53 %) 
X=1,108  
(210-4,060)





Iran Hamadan 8/132 (6 %)




Sari 1/136 (0.7 %) 1/136 (0.7 %) 20*** ELISA 33
Tabriz 
(rural) 20/91 (22 %)





Teheran 157/160 (98 %) 157/160 (98 %) X=8.2 (0.3-26.7) ELISA 34
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the winter (41). The highest AF-albumin adduct levels 
were found in children with acute hepatitis B, followed 
by children with chronic hepatitis, while healthy 
children had the lowest levels.
Although the immunotoxic effects of AFs in 
experimental animals are well known, there are no 
data on their immunotoxicity in children. In adults 
Jiang et al. (50) found a significant negative correlation 
between high AFB1-albumin adduct levels and the 
percentage of activated T and B cells. Denning et al. 
(51) believe that the immunotoxicity of AFs greatly 
contributed to acute lower respiratory tract infections 
in Filipino children, eleven of whom died, whereas 
Oyelami et al. (52.) found significant concentrations 
of AFs in the lung tissues of Nigerian children post 
mortem.
In a study of 479 blood samples taken from 
children from 9 months to five years in Benin and 
Togo, 99 % were positive for AF-alb adducts (42). In 
this and another longitudinal study of 400 children 
from Benin peak serum AF-alb adducts in fully 
weaned children was 2.5 times higher than in partially 
breast-fed children (23, 46). These authors also found 
negative correlation between AF-alb adducts and 
children weight and height (46). In another study of 
children from Sierra Leone, the authors suggested that 
the failure to thrive may have been caused by exposure 
to AFs and another mycotoxin - ochratoxin A (OTA) 
(53).
In tropical countries neonatal jaundice is very 
frequent. A Nigerian study of 327 neonates with 
jaundice and 60 controls has demonstrated that 
glucose-6-phosphate dehydrogenase deficiency and/
or the presence of aflatoxins in serum are the risk 
factors for neonatal jaundice (54). A study performed 
in Kenya showed that school children with 
hepatomegaly, which is very frequent in this country, 
had significantly higher levels of AF-alb adducts than 
children without hepatomegaly (55).
Some diseases that affect children in tropical 
regions, such as Rey’s syndrome and kwashiorkor 
were erroneously attributed to AF exposure (56, 57). 
Frequent post-mortem findings of AFs in various 
tissues of children with these diseases were probably 
the consequence and not the cause of liver injury. It 
is likely that their damaged liver could not metabolise 
the AFs.
Ochratoxin A
Ochratoxin A (OTA) is the most toxic and most 
common ochratoxin. Ochratoxins are produced by 
Penicillium verrucosum and several species of 
Aspergillus moulds from all over the world. They 
contaminate foodstuffs of plant origin (cereals, coffee 
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Europe
France 0/42 ELISA 30
Italy
Lombardi 1/231 (0.004 %) 1/231 (0.004 %) 194*** HPLC-FD 35
4/82 (5 %)




Turkey 75/75 (100 %) 75/75 (100 %) (60.9-300.0) HPLC-FD 37
South America
Brazil
1/50 (2 %) 1/50 (2 %)  24*** HPLC-FD 38
2/224 (0.01 %) 2/224 (0.01 %) 5*** HPLC-FD 39
2/100 (2 %) 2/100  (2 %) >0.3*** HPLC-FD 40
ND–not detected; HPLC-FD–high pressure liquid chromatography with fluorescent detection; ELISA–enzyme-linked immunosorbent 
assay
*In 13 samples both AFM1 and AFM2 were found
**In 95 % of samples the concentration of AFM1 was higher than 25 ng L-1
***Concentration in a single or both samples
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beans, raisins, wine, beer, and grape juice) and 
commodities of animal origin such as pork and poultry 
meat, eggs, milk, and dairy products due to the 
carryover effect. Most data on food contamination 
with this heat-stable mycotoxin are from Europe (58).
In experimental and domestic animals the main 
target organs of OTA toxicity are the kidney and liver, 
but it also affects the heart, blood (causing aberrations 
in coagulation factors), GI tract, lymphoid tissue, and 
bone marrow. OTA is readily absorbed by the upper 
GI tract and persists in the circulation for a long time 
due to binding to plasma proteins, enterohepatic 
circulation, and kidney resorption, enhanced by 
organic anion transporters (59). Its plasma half-life in 
humans is 35.55 days (60), which is extremely long 
and makes plasma OTA a good biomarker of exposure. 
There are several mechanisms involved in OTA 
toxicity: production of reactive oxygen species, 
inhibition of mitochondrial respiration, disruption of 
calcium homeostasis, inhibition of protein synthesis, 
and DNA damage (61-65). IARC has classified OTA 
as carcinogenic in experimental animals with limited 
evidence for its carcinogenicity in humans (Group 2B) 
(66).
Despite severe acute toxicity in laboratory animals, 
ochratoxicosis is quite rare in humans (67). So far, no 
ochratoxicosis has been reported in children. Some 
researchers believe that OTA is involved in the 
development of Balkan endemic nephropathy (BEN) 
and otherwise rare urothelial tumours, whose 
incidence is high in the endemic regions of the Balkans 
(68, 69). In several studies performed in the endemic 
regions of Bulgaria and Croatia the level of OTA or 
the frequency of OTA-positive food and human blood 
samples were higher than in control regions (for a 
more comprehensive review see 70). Low OTA 
concentrations are frequently found in blood and urine 
of apparently healthy persons in all countries where 
it was looked for, with significant geographical and 
seasonal variations (70-72). Various studies have 
demonstrated that the blood levels of OTA are higher 
in patients with chronic renal insufficiency treated 
with dialysis (for a review see 73).
In Europe the calculated daily human exposure to 
OTA ranges from 0.7 to 4.7 ng kg-1 body weight (b.w.), 
which is below the tolerable daily intake of 14 ng kg-1 
b.w. proposed by the Joint FAO/WHO Experts 
Committee on Food Additives and accepted by the 
European Scientific Committee (ESF) (57, 74). EFSA 
established the tolerable daily intake of 18 ng kg-1 b.w. 
(75).
Most data on child exposure to OTA are also from 
Europe. In Switzerland Zimmerli and Dick (76) 
reported twice as high OTA concentrations in the 
umbilical cord as that in maternal blood, indicating 
active transplacental transport of OTA.
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Table 3 Aflatoxin B1-albumin adducts in blood of children
Country Age (years) No. of positive/analysed
AFB1-alb adducts pg mg-1 
albumin  
Mean (95 % CI)
Ref.
Benin/Togo
Fully weaned >3 45.6 (38.8-53.7)
42Partially breast 
fed <3 18.0 (15.2-21.3)
Total 0.9-5 475/479 (99 %) 32.8 (5-1064)
Gambia
0.4 13/118 (11 %) 8.7 (5.0-30.3)* 19
Healthy
3-4




404/404 (100 %)  
6/6 96.9 (45.2-207.7)
Chronic HBV 
infection 34/34 (100 %) 44.9 (32.3-62.5)








(fmol mg-1 prot.) 105 3.47±0.85**
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OTA is also a frequent contaminant of breast milk. 
Its concentrations are about one quarter of those in 
maternal plasma (77) and the exposure of breast-fed 
children often exceeds the daily limit of 14 ng kg-1 
b.w. (Table 5). In colostrum OTA concentrations are 
much higher than in mature breast milk. Obviously, 
breast milk OTA contamination is related to maternal 
dietary habits, which may vary from country to 
country. In Italy, significantly higher OTA 
concentrations in breast milk correlate with the 
consumption of bread, bakery products, and pork meat 
(36), while in Norway they correlate with the 
consumption of liver paste (liverwurst, liver paté) and 
cakes (cookies, fruitcakes, chocolate cakes) (86). An 
Egyptian study (78) looked at a number of biochemical 
parameters in blood and urine of breast-fed children 
with high and low levels of OTA in maternal milk and 
children’s blood. Elevated OTA levels (in either milk 
or blood) correlated with a microglobulinuria, which 
was significantly greater in children with high than 
with low OTA concentrations and indicated initial 
kidney lesion. EFSA suggested that infants and 
children may experience higher rate of exposure than 
adults (75). It is not possible to link exposure to OTA 
during early childhood with any known human 
disease, although Schwartz (89) has put forward the 
hypothesis that mothers’ consumption of OTA-
contaminated food and OTA exposure in early 
childhood may be the cause of testicular cancer in 
adulthood. This theory is based on the correlation 
between the incidence of testicular cancer and per-
capita consumption of food items contaminated with 
OTA (coffee and pig meat) in 19 countries.
In tropical countries children are frequently 
exposed to OTA and AFs at the same time (44). Any 
health effect of this combination of mycotoxins, such 
as growth failure, could only be hypothesised (53). In 
a recent study in children in Cameroon under five years 
of age combined exposure to OTA and several other 
mycotoxins (AFs, fumonisin B1 – FB1, deoxynivalenol 
– DON, zearalenone – ZEA, α-zearalenol – α-ZEA 
and β-zearalenol β-ZEA) did not correlate with the 
degree of malnutrition (11).
Trichothecenes
Trichothecenes are a group of about 170 mycotoxins 
produced mostly by the moulds of the Fusarium strains 
that are common in mild climates. Other strains that 
produce them include Trichoderma, Trichothecium, 
Myrothecium, and Stachybotrys. Only a few types of 
trichothecenes are found in grains (wheat, oats, maize, 
barley) for human and animal consumption. The most 
common are deoxynivalenol (DON previously called 
vomitoxin), nivalenol (NIV), and diacetoxyscirpenol 
(DAS), while T-2 toxin is rare. IARC has designated 
DON, NIV, and T-2 toxin not classifiable as to 
carcinogenicity to humans (Group 3) (66). 
Trichothecenes inhibit protein synthesis and activate 
mitogen-activated protein kinases (MAPKs) that are 
involved in immune response and apoptosis signalling 
(90). The main characteristic of trichothecenes toxicity 
is immunomodulation. Lower doses increase 
resistance to pathogens, up-regulate many immune-
related genes, and elevate serum IgA levels. Higher 
doses injure tissues with high cellular turnover such 
as bone marrow, lymph nodes, thymus, spleen, and 
intestinal mucosa. The consequence is a weaker 
immune response. In general, trichothecenes are 
haematotoxic and immunotoxic without genotoxic and 
carcinogenic properties (91-94).
Large outbreaks of acute mycotoxicosis caused by 
T-2 toxin, called alimentary toxic aleukia (ATA), were 
seen in the USSR in the 1930s and 40s. This disease 
mostly affected people from 10 to 40 years of age from 
rural areas because of the ingestion of grains that 
remained beneath the snow in the fields over the winter 
(95). Breast-fed infants of mothers affected by ATA 
were not ill. The first symptoms were local irritation 
of oral mucosa and painful swallowing. They 
developed after a few hours of ingestion of 
contaminated grains and subsided after two to three 
days if the exposure ceased. If it continued, the disease 
progressed to the second, leukopoenic stage with 
minimal symptoms, and then to progressive 
leucopoenia ,  g ranulocytopoenia ,  re la t ive 
lymphocytosis, anaemia (low RBC or haemoglobin 
count), and thrombocytopoenia. In case of mild or 
discontinued exposure, patients would recover 
completely. The third stage was characterised by 
pharyngo-haemorrhagic symptoms with severe 
necro t ic  pharyngi t i s  and  pe tech ia l  rush , 
characteristically involving the trunk, inner sides of 
the arms and hips, and the inguinal fossae. These 
symptoms were accompanied by nose and mouth 
bleeds and bleeding in the stomach and intestines. This 
stage of ATA had a mortality rate of 50 %. The fourth 
stage was the recovery stage when leukocytes counts 
started to increase, but it was also the stage when 
bacterial infections such as pneumonia and purulent 
tonsillitis appeared. Several later outbreaks of 
trichothecene toxicosis were not so severe. A large 
outbreak in the Kashmir Valley (India) also affected 
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the children (96). Symptoms appeared 15 minutes to 
one hour after consuming contaminated bread; they 
were milder than in ATA and disappeared immediately 
after exposure ended. In the GI tract they included 
abdominal pain, diarrhoea, blood in the stool, and 
vomiting), but the most frequent were irritated throat 
and secondary infections of the upper respiratory tract.
Except for the study by Rubert et al. (97) there are 
no other reports of NIV and HT-2 toxin contamination 
of breast milk.
In animal studies trichothecenes turned out to be 
about 40 times more toxic when inhaled than when 
ingested (98). The outbreak of idiopathic pulmonary 
haemorrhage (IPH) in Cleveland (Ohio, US) between 
1993 and 1998 involved 37 children, mostly African 
American, who lived in humid houses damaged by 
flooding or plumbing and roof leaks (99). IPH was 
associated with exposure to satratoxin G and H and 
roridin that are produced by Stachybotrys chartarum 
on water-soaked cellulose walls. In 12 children the 
outcome was fatal, and 60 % of the children that 
returned home had recurrent pulmonary haemorrhage. 
It is not clear whether the toxins of S. chartarum 
caused IPH, as the Center of Disease Control declared 
that there was not enough evidence to confirm the 
suspicion (100).
Zearalenone
Zearalenone (ZEA) (previously also called F-2 
toxin) is mainly produced by Fusarium moulds. ZEA 
is a field contaminant of wheat, maize, oats, and barley, 
particularly in warm and temperate climates (101). It 
can also be found in surface waters close to agricultural 
areas (102).
In humans, ZEA is rapidly absorbed by the GI tract 
and metabolised to α-ZEA, β-ZEA, α-zearalenol 
(α-ZAL), and β-zearalenol (β-ZAL), which are then 
conjugated with glucuronic acid and rapidly excreted 
in bile and urine. Zearanol, a synthetic derivative of 
ZEA, is used as an anabolic agent for sheep and cattle 
in the USA, but in Europe it has been banned since 
1989.
In experimental animals ZEA is hepatotoxic, 
haematotoxic, immunotoxic, and genotoxic (101). It 
has low acute toxicity, and there are no reports of acute 
human ZEA mycotoxicoses. At chronic levels, ZEA 
and its derivatives show oestrogenic effect by binding 
to oestrogenic receptors and by modulating the activity 
of aldo-keto-reductases involved in the steroid 
synthesis. In female experimental and domestic 
animals they cause infertility, reduce litter size, 
increase embryonic resorption, reduce milk production, 
hypertrophy mammal glands, change weight of the 
thyroid, pituitary, and adrenal glands, and increase 
oestrins. In male animals they reduce testis weight, 
testosterone production, spermatogenesis, and mating 
drive and lead to feminisation.
Studies on experimental animals showed that ZEA 
crosses the placental barrier and is also excreted in 
breast milk. In a recent Spanish study (97), ZEA was 
found in 13 out of 35 samples of human breast milk 
(37 %) and its metabolites α-ZAL and β-ZAL in only 
one sample (2 %).
Historically, in Puerto Rico thousands of children 
experienced puberty, mainly due to environmental 
hormone contamination (103). Some of these children 
had ZEA in their blood, probably as the consequence 
of zearanol use as growth promoting agent in animal 
breeding. Since 1989, Hungary has seen an increase 
in the number of early telarche/mastopathy patients 
(104). Five out of them 36 had blood ZEA levels 
between 18.9 and 103.5 ng mL-1.
IARC has classified ZEA as a Group 3 carcinogen 
(66), but recent documents classify it and its 
metabolites as endocrine disruptors (105).
Fumonisins
Fumonisins are a group of 15 mycotoxins produced 
by Fusarium moulds (mostly F. verticilloides and F. 
moniliforme). In naturally contaminated grains the 
most frequent is fumonisin B1 (FB1), often 
accompanied by small amounts of fumonisin B2 (FB2) 
and fumonisin B3 (FB3).
Fumonisins contaminate various grains, but are 
most common in maize (106). They are poorly 
absorbed by the GI tract and quickly eliminated from 
plasma with low accumulation in the kidney and liver. 
They exert their toxic effects by inhibiting ceramide 
synthase, the key enzyme in the sphingolipid 
metabolism. This results in lower sphingolipid de novo 
synthesis and reuse of sphinganine. Significantly 
increased blood sphinganine affects the membrane 
transport of folic acid by binding to folate receptors, 
which eventually leads to lower folate uptake (107).
Fumonisins target different organs in domestic and 
experimental animals: in horses they cause 
leukoencephalomalacia, in pig pulmonary oedema, in 
rats they are predominantly nephrotoxic, and in mice 
they are hepatotoxic and teratogenic, causing neural 
tube defects (NTD) (2).
There is a only one report of acute fumonisin-
caused mycotoxicosis that occurred in India (108). 
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Symptoms appeared after ingestion of contaminated 
sorghum or maize and included abdominal pain, 
borborygmi, and diarrhoea. The disease was self-
limiting, and preschool children were less affected.
In some regions where maize is staple food 
(Transkei in Southern Africa, China, and Northern 
Italy) the high frequency of oesophageal cancers is 
believed to be related to exposure to fumonisins or 
their producers (F. moniliforme) (109, 110). In the 
early 1990s, a higher prevalence of NTD (anencephaly 
and spina bifida) was observed in children born along 
the Texan and Mexican border by Mexican-American 
women, and Hendricks et al. (111) suggested that this 
was caused by fumonisin exposure in the first trimester 
of pregnancy. High prevalence of NTD was also found 
in the Transkei region in Southern Africa (112), 
northern Iran (113), and several regions of China, 
where it was higher in rural than in urban population 
(114). In a large controlled study in China (130,142 
women taking folic acid vs. 117,689 controls) the 
incidence of NTD was significantly decreased by folic 
acid supplementation (115). In Ireland, B12 and folic 
acid fortification of breakfast cereals decreased the 
rate of NTD from 47 to 13 per 10,000 births (116). In 
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Egypt 43/120 (36 %)
21.06±13.7 
(5.07-45.01) HPLC-FD NI NI 25.
36/50 (72 %) NI HPLC/Mf NI NI 78
Sierra Leone 40/113 (35 %) NI  200-337,000 HPLC-FD 200 NI 79
Americas
Brazil 0/224 NI HPLC-FD NI 0.0003 39
Sao Paolo 2/50 (4 %) 10, 24 HPLC-FD NI 10 38
Ribeirão 
Preto-SP 66/100 (66 %)
4  
(0.3-21) HPLC-FD 0.3 0.8 40
Chile
9/9 (100 %) 106±45  (44-184) HPLC-FD NI NI 77
40/50 (80 %) 52±56  (10-186) HPLC-FD 10 30 80
Asia
Iran, Sari 2/136 (1 %) 90, 140 ELISA HPLC-FD NI NI 33
Australia
Victoria 2/100 (2 %) 3, 3.6 HPLC-FD 1.6 NI 81
Europe
Italy
9/50 (18 %) 4189  (1700-6,600) HPLC-FD 200 NI 82
22/111 (20 %) (100-12,000) HPLC-FD 100 NI 83
74/85 (75 %) NI NI 20 NI 84
61/82 (74 %) 30.43±66.9  (5-405) HPLC-FD 2 5 36
198/231 (86 %) 6.01±8.31  (1-57) HPLC-FD 0.5 NI 35
Norway
38/115 (33 %) (10-130) HPLC-FD NI 10 85
17/80 (21 %) 30  (10-182) HPLC-FD NI 10 86
Slovakia 23/76 (30 %) (2.3-60.3) HPLC-FD 4.8 14.4 87
Sweden 23/40 (58 %) (10-40) HPLC-FD 10 40 88
Switzerland 4/40 (10 %) 7.2 (5-14) HPLC-FD NI 5 76
Turkey 75/75 (100 ) (620-13,111) HPLC-FD 10 NI 37
NI-not indicated
*LC/Mf: liquid chromatography with microfluorimetric detection
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order to decrease the incidence of NTD, the US Food 
and Drug Administration (FDA) mandated fortification 
of grain products with folic acid (117). This resulted 
in lower NTD incidence in the general population, but 
not in several ethnic groups. There are reports of a 
58 % drop in NTD occurrence rate and of an even 
more significant (95 %) drop in NTD recurrence rate 
when folate supplementation was applied starting one 
month before conception (116). However, some 
studies reported that folate supplementation was not 
that effective or not effective at all, and the disturbance 
of folate metabolism by fumonisins has not been 
confirmed, although there is no doubt about their 
neurotoxicity in experimental animals (118-120).
IARC has classified fumonisins as carcinogenic in 
experimental animals with limited evidence of its 
carcinogenicity in humans (Group 2B carcinogen) 
(66).
Ergot
Ergot alkaloids are a group of about 40 toxins 
produced mostly by the fungal species of the genus 
Claviceps that contaminate rye, oats, and pearl millet. 
They are also produced by some strains of Penicillium, 
Aspergillus, and Rhizopus spp. (121). These toxins 
may be divided in three groups: lysergic acid 
derivatives (e.g. ergotamine and ergocristine), 
isolysergic acid drivatives (e.g. ergotaminine), and 
dimethylergoline derivatives (e.g. agroclavine) (122). 
Ergot is the name of sclerotia, a dark fungal mass that 
replaces the seed or kernel of the infected plant. Ergot 
poisoning is called ergotism and was common in 
European history (123).
The clinical presentation of acute ergotism depends 
on the type of toxins that are produced by particular 
strains of the genus Claviceps.
Ergot alkaloids are absorbed by the GI tract, 
distributed readily in plasma, and metabolised by 
CYP3A4. Some of them are conjugated with 
glucuronic acid and eliminated by biliary excretion 
(124).
Claviceps purpurea produces toxins from the 
group of lysergic acid derivatives (ergotamine and 
ergocristine), which cause severe vasoconstriction. 
Poisoning symptoms include severe pain in the legs, 
loss of pulse, and oedema. Paraesthesia is followed 
by gangrene around the tendons, with painless 
demarcation. In the ergotism outbreak in Wollo 
(Ethiopia) in 1977-78 four children lost one or both 
legs (125).
Clavine alkaloids produced by Claviceps fusiformis 
can cause the convulsive type of ergotism that occurs 
1-48 hours after ingestion of contaminated food. It 
starts with gastrointestinal symptoms (nausea, 
vomiting, dizziness) and continues with the nervous 
system symptoms (crawling sensation in the skin, 
tingling in the fingers, vertigo, headache drowsiness, 
prolonged sleepiness, painful muscular contractions 
leading to convulsions, blindness, and paralysis). 
Mental disturbances may appear such as mania, 
psychosis, and delirium. One notable historical case 
presented by Caporeal (126) were the teenage girls 
accused of witchcraft in Salem in 1692.
3-nitropropionic acid
3-nitropropionic acid (3-NPA) is produced by 
Arthrinium moulds and causes the so called mouldy 
sugar cane disease (127). This disease appears in the 
late winter months (February and March) in 13 
northern Chinese counties and affects children who 
consume sugar cane contaminated with Arthrinium 
moulds stored for at least two months. From 1978 to 
1988, 884 persons were involved in a series of small 
epidemics (involving usually up to five children), and 
88 (10 %) died (128). The first symptoms appeared 
two to three hours after the consumption of sugar cane 
and included vomiting, general fatigue, convulsions, 
carpopedal spasms, and coma. Dystonia appeared in 
10-50 % of the cases as the consequence of basal 
ganglia necrosis. These last symptoms can be 
predicted if the basal ganglia are scanned with 
computerised tomography (CT) (129). In adults, the 
symptoms of 3-NPA poisoning include mild 
disturbances of the GI tract and brain lesions, but these 
are very rare. Since 1995, there have been no further 
reports on mouldy sugar cane disease in the available 
scientific literature. However, Chinese health 
authorities keep issuing warnings in daily newspapers, 
which suggests that this disease is still a threat.
Ustilago maydis toxins
Historically, mycotoxicoses that appeared in 
Croatia between the two world wars were suspected 
to be caused by corn smut (Ustilago maydis). Children, 
infants, and toddlers, suspected of ustilaginism fell ill 
between March and May after a winter of almost 
exclusive consumption of corn flour from fields 
infested with corn smut. The clinical presentation was 
either acute - with acropathic symptoms including 
hand and sole pruritus, oedema and erythema - or 
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chronic - with frequent relapses of acute symptoms 
and abundant skin desquamation (130, 131). At the 
time, it was believed that the cause were corn smut 
spores at a specific window of maturity. If the corn 
was consumed before or after that window, it was 
considered harmless. This corn smut hypothesis has 
never been confirmed, and the only argument in its 
favour is that the patient’s condition would improve 
as soon (several days to a fortnight) as the corn flour 
was removed from the diet. No similar phenomena 
have been reported since 1945.
CONCLUSION
Acute mycotoxicoses in children are serious 
diseases, mostly diagnosed only when an epidemics 
breaks out, affecting several children. They should be 
suspected when the disease cannot be explained by 
infection with a known microorganism. Acute 
mycotoxicoses are more frequent in tropical regions 
but are no stranger to temperate climates as well. 
Chronic mycotoxicoses may appear all over the world 
and paediatricians should keep in mind that their 
clinical manifestations vary a lot.
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Mikotoksikoze su akutna i kronična trovanja toksinima plijesni koji se nazivaju mikotoksini. Odrasle osobe 
i djeca stalno su izloženi niskim koncentracijama mješavine mikotoksina, većinom putem kontaminirane 
hrane. Akutne toksikoze koje uzrokuje izloženost velikim količinama mikotoksina danas su rijetke te su 
opisane kako bi se liječnici i drugo zdravstveno osoblje informirali o njihovim simptomima koji mogu 
oponašati druge bolesti. Djeca su osjetljivija na toksični učinak mikotoksina zbog toga što je njihova 
tjelesna masa manja, a neki sustavi za detoksikaciju nisu u potpunosti razvijeni. Neke se mikotoksikoze 
javljaju samo u djece ili su u djece simptomi jače izraženi. Podrobnih podataka o epidemiologiji 
mikotoksikoza u dječjoj dobi nema jer one pogađaju prvenstveno najsiromašnije, uglavnom u zemljama 
tropskoga pojasa gdje je zdravstvena služba nedostatna, a potrebe stanovništva za liječenjem velike. U tim 
se zemljama češće javljaju i kronične mikotoksikoze, no ima ih i u zemljama s umjerenom klimom. U 
razvijenim su zemljama zdravstvene vlasti više zabrinute zbog izloženosti djece niskim koncentracijama 
mikotoksina koji imaju imunotoksična, genotoksična i kancerogena svojstva.
KLJUČNE RIJEČI: 3-NPA; aflatoksini; ergot; fumonizini; okratoksini; trihoteceni; toksini Ustilago 
maydis; zearalenon
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